Lijfering Willem M, de Vries Aiko P J, Veeger Nic J G M, van Son Willem J, Bakker Stephan J L, van der Meer Jan
Division of Haemostasis, Thrombosis and Rheology, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Thromb Haemost. 2008 Jan;99(1):127-32. doi: 10.1160/TH07-05-0340.
Renal transplant recipients are at an increased risk of venous thrombosis, which has been regarded as a postoperative complication, although it may persist afterwards. As numerous case reports have shown that active cytomegalovirus (CMV) infection can be found at time of onset of venous thrombosis, and is frequently found in renal transplant recipients, we hypothesized that one might be the result of the other. To calculate the risk of (recurrent) venous thrombosis in renal transplant recipients, and to see whether CMV infection influenced this risk, we retrospectively analysed 606 living consecutive renal transplant recipients. CMV status at time of transplantation and at time of enrolment was determined. Absolute risks of first venous thrombosis and recurrence were compared with CMV status, and were corrected for surgery related venous thrombosis, age, and anticoagulant treatment. Annual incidence of venous thrombosis was 0.88% (95% CI, 0.65-1.15) in all recipients and 0.59% (95% CI, 0.41-0.83) corrected for surgery related venous thrombosis. CMV positive and seroconverted recipients tended to have an increased risk of venous thrombosis compared to CMV negative recipients; corrected relative risks were 2.0 (95% CI, 0.9-5.2) and 1.7 (95% CI, 0.6-4.7), respectively. The cumulative 10-year recurrence rate of venous thrombosis in CMV seronegative, seroconverted, and seropositive recipients was 10%, 51% and 59%, respectively. We conclude that CMV infection tended to be associated with an increased risk of (recurrent) venous thrombosis. Prospective studies are warranted to establish this observation, which suggests that CMV infection influences the high risk of (recurrent) venous thrombosis in renal transplant recipients.
肾移植受者发生静脉血栓形成的风险增加,这一直被视为术后并发症,尽管术后仍可能持续存在。由于大量病例报告显示,静脉血栓形成发作时可发现活动性巨细胞病毒(CMV)感染,且在肾移植受者中经常发现,我们推测两者可能互为因果。为了计算肾移植受者(复发性)静脉血栓形成的风险,并观察CMV感染是否影响这一风险,我们回顾性分析了606例连续的活体肾移植受者。确定了移植时和入组时的CMV状态。将首次静脉血栓形成和复发的绝对风险与CMV状态进行比较,并对手术相关静脉血栓形成、年龄和抗凝治疗进行校正。所有受者静脉血栓形成的年发病率为0.88%(95%CI,0.65-1.15),校正手术相关静脉血栓形成后为0.59%(95%CI,0.41-0.83)。与CMV阴性受者相比,CMV阳性和血清转化的受者发生静脉血栓形成的风险往往增加;校正后的相对风险分别为2.0(95%CI,0.9-5.2)和1.7(95%CI,0.6-4.7)。CMV血清阴性、血清转化和血清阳性受者静脉血栓形成的累积10年复发率分别为10%、51%和59%。我们得出结论,CMV感染往往与(复发性)静脉血栓形成风险增加有关。有必要进行前瞻性研究以证实这一观察结果,这表明CMV感染影响肾移植受者(复发性)静脉血栓形成的高风险。